Giant cell myositis and myocarditis revisited

Area of Science:

• Autoimmune Diseases
• Cardiology
• Neurology

Background:

• Giant cell myositis (GCMm) and giant cell myocarditis (GCMc) are rare autoimmune conditions.
• Giant cell myocarditis (GCMc) is a life-threatening disease with a 70% 1-year mortality rate due to lethal arrhythmias, rapid heart failure, and sudden death.
• GCMc is believed to be T-cell mediated and characterized by myofiber necrosis and giant cells on biopsy.

Purpose of the Study:

• To highlight the critical importance of recognizing and promptly managing giant cell myocarditis (GCMc).
• To emphasize the association of GCMc with thymoma, myasthenia gravis, and orbital myositis.
• To advocate for early intervention strategies in high-risk patients.

Main Methods:

• Review of existing literature on giant cell myositis and myocarditis.
• Analysis of clinical characteristics and outcomes associated with GCMc.
• Identification of co-manifesting conditions and diagnostic challenges.

Main Results:

• Giant cell myocarditis (GCMc) presents a significant mortality risk, necessitating emergency attention.
• Co-occurrence with thymoma, myasthenia gravis, and orbital myositis is common.
• Suspicion and vigilance are key diagnostic approaches for physicians managing these associated conditions.

Conclusions:

• Prompt diagnosis and combined immunosuppressive treatment are vital for improving outcomes in GCMc.
• Early involvement of heart failure teams is essential for managing this critical condition.
• Physicians should maintain a high index of suspicion for GCMc in patients with thymoma, myasthenia gravis, or orbital myositis.